cisplatin
Showing 1 - 25 of 1,923
Pancreatic Adenocarcinoma, Homologous Recombination Deficiency Trial (Cisplatin)
Not yet recruiting
- Pancreatic Adenocarcinoma
- Homologous Recombination Deficiency
- Cisplatin
- (no location specified)
Oct 18, 2023
Pancreatic Cancer Trial in Baltimore (Gemcitabine, Cisplatin, Pembrolizumab)
Not yet recruiting
- Pancreatic Cancer
- Gemcitabine
- +2 more
-
Baltimore, MarylandSKCCC Johns Hopkins
Aug 16, 2023
Locally Advanced Cervical Cancer Trial in Xi'an (Zimberelimab, Albumin-bound Paclitaxel, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- Zimberelimab
- +2 more
-
Xi'an, Shaanxi, ChinaHongxi Zhao
Sep 20, 2023
Cholangiocarcinoma Trial in Houston (Pembrolizumab, Gemcitabine, Cisplatin)
Not yet recruiting
- Cholangiocarcinoma
- Pembrolizumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Jul 21, 2023
Neuroendocrine Carcinoma of the Bladder, Bladder Cancer Trial (Adebrelimab, Etoposide, Cisplatin)
Not yet recruiting
- Neuroendocrine Carcinoma of the Bladder
- Bladder Cancer
- Adebrelimab
- +3 more
- (no location specified)
Oct 14, 2023
Chemo;Advanced Gastric Cancer;Cisplatin;Disulfiram Trial in Hangzhou (disulfiram and cisplatin, cisplatin)
Not yet recruiting
- Chemotherapy；Advanced Gastric Cancer；Cisplatin；Disulfiram
- disulfiram and cisplatin
- cisplatin
-
Hangzhou, Zhejiang, ChinaHangzhou first people's Hospital
Dec 26, 2022
Ovarian Cancer, Malignant Tumor of Uterus Trial in New York (Sacituzumab, Cisplatin)
Not yet recruiting
- Ovarian Cancer
- Malignant Neoplasm of Uterus
- Sacituzumab
- Cisplatin
-
New York, New YorkIcahn School of Medicine at Mount Sinai Division of Hematology a
Sep 14, 2023
Biliary Tract Carcinoma, Cholangiocarcinoma, Bile Duct Cancer Trial in Madison (Gemcitabine, Cisplatin, Zimberelimab)
Not yet recruiting
- Biliary Tract Carcinoma
- +2 more
- Gemcitabine
- +3 more
-
Madison, WisconsinUniversity of Wisconsin
Sep 15, 2023
Epithelial Ovarian Cancer, Acute Kidney Injury Due to Circulatory Failure Trial (Sodium Sulfate, Hydration, Cisplatin)
Not yet recruiting
- Epithelial Ovarian Cancer
- Acute Kidney Injury Due to Circulatory Failure
- Sodium Sulfate
- +2 more
- (no location specified)
May 17, 2023
Head Neck Cancer Trial in Billerica, Darmstadt (Xevinapant, Cisplatin, intensity-modulated radiation therapy (IMRT))
Not yet recruiting
- Head and Neck Cancer
- Xevinapant
- +2 more
-
Billerica, Massachusetts
- +1 more
Sep 20, 2023
Nasopharyngeal Carcinoma Trial in Guangzhou (Camrelizumab, Gemcitabine, Cisplatin)
Recruiting
- Nasopharyngeal Carcinoma
- Camrelizumab
- +3 more
-
Guangzhou, Guangdong, ChinaDepartment of Nasopharyngeal Carcinoma, Sun Yat-sen University C
May 3, 2023
Cholangiocarcinoma Non-resectable Trial in Chengdu (Candonilimab, Cisplatin, Gemcitabine)
Recruiting
- Cholangiocarcinoma Non-resectable
- Candonilimab
- +2 more
-
Chengdu, Sichuan, ChinaWest China Hospital, Sichuan University
Aug 4, 2023
Malignant Pleural Mesothelioma, Mesothelioma Trial in Tampa (Cisplatin, Methotrexate, Gemcitabine)
Active, not recruiting
- Malignant Pleural Mesothelioma
- Mesothelioma
- Cisplatin
- +3 more
-
Tampa, FloridaH. Lee Moffitt Cancer Center and Research Institute
Jan 5, 2023
Esophageal Squamous Cell Cancer Trial in Beijing (Toripalimab, Paclitaxel, Cisplatin)
Recruiting
- Esophageal Squamous Cell Cancer
- Toripalimab
- +2 more
-
Beijing, Beijing, ChinaBeijing Cancer Hospital / Peking University Cancer Hospital
Jan 30, 2023
Locally Advanced Cervical Cancer, Gemcitabine, Chemo-radiotherapy Trial in México (Gemcitabine, Cisplatin)
Recruiting
- Locally Advanced Cervical Cancer
- +2 more
- Gemcitabine
- Cisplatin
-
México, Ciudad De México, MexicoNational Cancer Institute of Mexico
Nov 27, 2023
Head Neck Cancer Trial in Singapore (carboplatin,, cisplatin, gemcitabine HCl)
Active, not recruiting
- Head and Neck Cancer
- carboplatin,
- +4 more
-
Singapore, SingaporeNational Cancer Centre - Singapore
Sep 27, 2022
Esophageal Squamous Cell Carcinoma Trial (LY01015, Fluorouracil, Cisplatin)
Not yet recruiting
- Esophageal Squamous Cell Carcinoma
- LY01015
- +3 more
- (no location specified)
Aug 28, 2023
Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)
Not yet recruiting
- Borderline Resectable Carcinoma
- Biliary Tract Cancer
- Durvalumab
- +4 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023
Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable Trial in Guangzhou (Cetuximab, Zimberelimab, Docetaxel)
Not yet recruiting
- Hend and Neck Squamous Cell Carcinoma Locally Advanced Operable
- Cetuximab
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University
Oct 24, 2023
Advanced Biliary Tract Cancer Trial in Guangzhou (Envofolimab, Lenvatinib, Gemcitabine)
Recruiting
- Advanced Biliary Tract Cancer
- Envofolimab
- +3 more
-
Guangzhou, Guangdong, ChinaThe First Affiliated Hospital of Sun Yat-sen University
Oct 11, 2022
Nasopharyngeal Carcinoma, Nasopharyngeal Tumors, Nasopharyngeal Diseases Trial in Guangzhou (Nimotuzumab, Cisplatin)
Recruiting
- Nasopharyngeal Carcinoma
- +3 more
- Nimotuzumab
- Cisplatin
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Nov 3, 2022
Oral Squamous Cell Carcinoma, Neoadjvant Therapy, Anti-PD-1 Trial in Shanghai (Toripalimab (anti-programmed death-1 inhibitor),
Recruiting
- Oral Squamous Cell Carcinoma
- +3 more
- Toripalimab (anti-programmed death-1 inhibitor)
- +4 more
-
Shanghai, Shanghai, ChinaNinth People's Hospital, Shanghai Jiao Tong University School of
Oct 8, 2022
Oral Squamous Cell Carcinoma Trial (Tislelizumab, Albumin paclitaxel, Cisplatin)
Not yet recruiting
- Oral Squamous Cell Carcinoma
- Tislelizumab
- +3 more
- (no location specified)
May 7, 2023
Nasopharyngeal Carcinoma, Nasopharyngeal Tumors, Nasopharyngeal Diseases Trial in Guangzhou (gemcitabine and cisplatin,
Recruiting
- Nasopharyngeal Carcinoma
- +3 more
- gemcitabine and cisplatin
- +3 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
May 4, 2022